Insider Buying: Stereotaxis (NYSEAMERICAN:STXS) Director Purchases 10,000 Shares of Stock

Stereotaxis Inc. (NYSEAMERICAN:STXS) Director Paul Isaac purchased 10,000 shares of the stock in a transaction on Monday, November 17th. The shares were purchased at an average cost of $2.18 per share, for a total transaction of $21,800.00. Following the acquisition, the director directly owned 97,299 shares of the company’s stock, valued at approximately $212,111.82. This represents a 11.45% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Stereotaxis Stock Up 7.8%

NYSEAMERICAN STXS traded up $0.17 during trading hours on Tuesday, reaching $2.29. The company’s stock had a trading volume of 694,472 shares, compared to its average volume of 477,972. Stereotaxis Inc. has a 1 year low of $1.54 and a 1 year high of $3.59. The firm’s 50-day moving average price is $2.92 and its 200-day moving average price is $2.54. The company has a market capitalization of $208.09 million, a price-to-earnings ratio of -7.88 and a beta of 1.65.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of STXS. BNP Paribas Financial Markets lifted its holdings in shares of Stereotaxis by 106.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,461 shares of the company’s stock worth $36,000 after acquiring an additional 5,910 shares during the last quarter. XTX Topco Ltd purchased a new stake in Stereotaxis in the 1st quarter worth about $37,000. Schonfeld Strategic Advisors LLC purchased a new position in shares of Stereotaxis during the third quarter valued at approximately $38,000. Moneta Group Investment Advisors LLC bought a new position in shares of Stereotaxis during the third quarter valued at approximately $43,000. Finally, Boothbay Fund Management LLC purchased a new stake in shares of Stereotaxis in the third quarter worth approximately $54,000. Institutional investors own 45.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on STXS. Roth Capital reissued a “buy” rating and set a $4.00 price target on shares of Stereotaxis in a research note on Wednesday, November 12th. UBS Group set a $4.00 target price on Stereotaxis in a research report on Wednesday, November 5th. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $4.00.

About Stereotaxis

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.